Camzyos (Mavacamten)

Mavacamten is a medicine for obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is too thick and squeezes too hard. It is taken as a capsule once a day. It works by relaxing the heart muscle a little so blood can flow out of the heart more easily.

Brand names:Camzyos
Medication

What people taking Camzyos (Mavacamten) report

Every report comes from a Lived member, sent anonymously.

Have you tried Camzyos (Mavacamten) for HCM (Hypertrophic Cardiomyopathy)?

NameHow it went

About Camzyos (Mavacamten)

What It's For

Mavacamten, sold as Camzyos, is a prescription capsule for obstructive hypertrophic cardiomyopathy (HCM) that is causing symptoms. In HCM the heart muscle is abnormally thick, and in the obstructive form the thickened wall narrows the path blood takes as it leaves the heart's main pumping chamber. That narrowing can cause shortness of breath, chest discomfort, tiredness, dizziness or fainting, often during exertion. Mavacamten is approved for adults and for children who weigh at least 30 kg (66 pounds), to ease symptoms and improve the ability to be active. It was the first of a newer group of medicines called cardiac myosin inhibitors, which act directly on the heart muscle's overactive contraction. Beta blockers and calcium channel blockers have long been used to relieve HCM symptoms, and some people have a procedure to remove or shrink part of the thickened wall. Mavacamten is often considered when symptoms continue despite those medicines. It does not cure HCM, and it is approved only for the obstructive form.

How It Works

Heart muscle contracts when myosin, a motor protein inside each muscle cell, grabs neighboring filaments and pulls. In HCM, too much myosin is active at once, so the muscle squeezes harder than it needs to and relaxes poorly. When the thickened wall squeezes forcefully, it can pinch the outflow path, and the heart ends up pumping against its own blockage. Mavacamten attaches to heart muscle myosin and keeps more of it in a resting state, so less of it pulls with each beat. The heart squeezes somewhat less forcefully, the obstruction eases and pressures inside the heart fall as it fills between beats. The effect is reversible and fades over weeks after the last dose. The same action explains the main risk: if pumping strength drops too far, heart failure can develop. That is why the dose is guided by heart ultrasound rather than by symptoms alone.

Dosage & Administration

Mavacamten is a capsule taken once a day, with or without food. Adults usually start at 5 mg. Children start at 5 mg or 2.5 mg depending on weight. The dose is then adjusted among a few fixed strengths, up to 15 mg, based on symptoms and echocardiograms (ultrasound scans of the heart). Two measurements guide each decision. The ejection fraction is the percentage of blood the main pumping chamber pushes out with each beat. Treatment is not started if it is below 55%, and it is paused if it falls below 50% at any visit. The outflow gradient, measured in millimeters of mercury (mmHg), shows how much pressure builds up behind the narrowing, and it is often checked while the person bears down as if straining (the Valsalva maneuver). The aim is to lower the gradient while keeping pumping strength in a safe range. Levels take weeks to settle after each change, and genetics and other medicines can make them differ widely between people, so dose changes follow a set schedule. Swallow capsules whole without opening, breaking or chewing them. If a dose is missed, take it as soon as possible that day and return to the usual time the next day; never take two doses on the same day. If too much is taken, call the prescriber or go to the nearest emergency room right away, because a large dose can weaken the heart's pumping too far. Because of the heart failure risk, Camzyos is available only through a restricted safety program, the Camzyos REMS (Risk Evaluation and Mitigation Strategy). The prescriber and the pharmacy must be certified, the patient enrolls and keeps up with monitoring, and the medicine comes from a certified pharmacy rather than a local one. The pharmacy also checks for drug interactions before each fill.

Side Effects

Dizziness is the most common side effect. In the main trial it affected about 27% of people taking mavacamten compared with 18% on placebo, and fainting occurred in about 6% compared with 2%. Because dizziness and fainting can also come from HCM itself, new or more frequent episodes are worth reporting rather than assuming they are harmless. The most important risk, and the subject of a boxed warning, is heart failure from the heart pumping too weakly. In that trial, about 6% of people on mavacamten had their ejection fraction fall below 50%, and in each case it recovered after the medicine was paused. Some of these drops cause no symptoms, which is why scheduled echocardiograms matter even when someone feels well. Tell the care team or get medical help right away for new or worsening shortness of breath, swelling in the legs, chest pain, a racing heartbeat (palpitations), unusual tiredness or rapid weight gain.

Interactions & Warnings

Mavacamten is broken down mainly by two liver enzymes. Medicines that block these enzymes can raise mavacamten levels and push the heart toward failure. Medicines that speed the enzymes up can lower levels so the drug stops working, and stopping such a medicine later can let levels climb. Some combinations are not allowed at all, many others need a dose change and an extra echocardiogram, and even a short course of a new medicine may mean pausing mavacamten while it is taken. This includes over-the-counter heartburn medicines such as omeprazole (Prilosec), esomeprazole (Nexium) and cimetidine (Tagamet), as well as grapefruit juice. Mavacamten can also lower the levels of some other medicines, including certain hormonal birth control described below. Check every new prescription, nonprescription medicine and supplement with the prescriber or pharmacist before starting or stopping it. Because mavacamten weakens the heart's squeeze, its effect adds to other medicines that do the same. It should be avoided with disopyramide, an older heart rhythm medicine sometimes used for HCM, with ranolazine, a chest pain (angina) medicine, and with verapamil or diltiazem, two calcium channel blockers that slow the heart and are sometimes used for HCM symptoms, when either is combined with a beta blocker. Starting or raising any beta blocker or calcium channel blocker calls for closer monitoring. Based on animal studies, mavacamten may harm a developing baby. A pregnancy test is done before starting, and people who can become pregnant need effective birth control during treatment and for 4 months after the last dose. Mavacamten can make some combined hormonal birth control less effective. Products combining ethinyl estradiol with norethindrone can be used; with other combined products, a barrier method such as condoms is added, or a method not affected by this interaction, such as an intrauterine device (IUD), is used instead. Tell the prescriber right away about a known or suspected pregnancy. Whether mavacamten passes into breast milk is unknown.

What to Expect

Mavacamten works gradually. In the main trial, the obstruction seen on ultrasound had already dropped by week 4, while changes in breathlessness and exercise ability were judged over months. Responses vary. After 30 weeks, 37% of people on mavacamten met a combined goal of better exercise capacity and less limiting symptoms, compared with 17% on placebo. In a second study of people with severe symptoms who were already being considered for a procedure to reduce the thickened wall, about 1 in 5 on mavacamten still qualified for or chose the procedure after 16 weeks, compared with about 3 in 4 on placebo. The first months involve visits and echocardiograms every few weeks while the dose is set, followed by regular checks for as long as the medicine is taken. Between visits, tell the care team about a serious infection, an irregular heartbeat such as atrial fibrillation, or any change in other medicines, since these raise the risk of heart failure and the dose may be held or lowered. Mavacamten eases obstruction and symptoms rather than curing HCM, and its effect wears off after stopping: in the trial, obstruction returned to its starting level about 8 weeks after the last dose. Whether it changes long-term outcomes such as survival is not yet known, so usual HCM follow-up continues alongside it.

Questions to Ask Your Doctor

  1. 1.Why is mavacamten a better fit for me now than adjusting my current medicines or considering a procedure to reduce the thickened wall?
  2. 2.Which of my current medicines, including over-the-counter heartburn drugs and supplements, need to change before I start?
  3. 3.How often will I need echocardiograms, and what results would lead you to pause or change my dose?
  4. 4.How will we judge whether it is working, and what would we try if my symptoms do not improve?
  5. 5.What birth control works with mavacamten, and what should I do if I am planning a pregnancy?

Last reviewed • Oct 2026

Educational content, not medical advice.